Last reviewed · How we verify

NCT07090564

Treatment Outcomes in PASC Patients With Neurocognitive Impairment

Completed Last updated 3 March 2026
What this trial tests

trial in Long COVID in 171 participants. Completed in 1 April 2024.

Timeline
12 October 2022
Primary endpoint
31 March 2024
1 April 2024

Quick facts

Lead sponsorOhio State University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment171
Start date12 October 2022
Primary completion31 March 2024
Estimated completion1 April 2024
Sites1 location across United States

Conditions studied

Sponsor

Ohio State University

Who can join

18 and older, any sex, with Long COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Longitudinal study collecting retrospective and prospective data on treatments received and change in quality of life among patients with neurocognitive symptoms attending a Long COVID clinic

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Long COVID

Currently open trials in the same condition.

Other Ohio State University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07090564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing